MARKET

NVAX

NVAX

Novavax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

98.44
-12.38
-11.17%
After Hours: 98.00 -0.44 -0.45% 19:59 01/18 EST
OPEN
107.30
PREV CLOSE
110.82
HIGH
107.53
LOW
98.00
VOLUME
6.55M
TURNOVER
--
52 WEEK HIGH
331.68
52 WEEK LOW
98.00
MARKET CAP
7.44B
P/E (TTM)
-6.6443
1D
5D
1M
3M
1Y
5Y
Gates, Wellcome pledge $150 mln each to pandemic preparedness group
reuters.com · 5h ago
BRIEF-Mabion Signs Statement Of Work With Novavax
reuters.com · 12h ago
Why Moderna, Pfizer, BioNTech And Novavax Shares Are Falling Today
Shares of vaccine makers, including Moderna Inc (NASDAQ: MRNA), BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc.
Benzinga · 12h ago
Life Sciences in selloff: BofA says “2021 is a tough act to follow”
Falling ~4.9% year-to-date, the healthcare sector in the S&P 500 ended the week as the second-worst performer in the broader index for the year so far. Life Sciences Tools and Services
Seekingalpha · 3d ago
Edge Wealth Management LLC Buys SPDR Biotech ETF, Salesforce. ...
New York, NY, based Investment company Edge Wealth Management LLC (Current Portfolio) buys SPDR Biotech ETF, Salesforce.com Inc, Invesco BulletShares 2024 Corporate Bond ETF, Invesco Senior Loan ETF, iShares J.P.
GuruFocus.com · 4d ago
Novavax Still Has Not Received an FDA EUA as the Market Waits
Investor Place · 4d ago
Why Moderna, Novavax And Other Vaccine Stocks Are Extending Losses Today
COVID-19 vaccine stocks are all retreating sharply for a second day running on Friday.
Benzinga · 4d ago
France's HAS says Novavax and Janssen vaccines are good alternative
reuters.com · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVAX. Analyze the recent business situations of Novavax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
42.86%Buy
42.86%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NVAX stock price target is 270.00 with a high estimate of 315.00 and a low estimate of 209.00.
High315.00
Average270.00
Low209.00
Current 98.44
EPS
Actual
Estimate
-3.80-2.85-1.90-0.95
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 495
Institutional Holdings: 41.96M
% Owned: 55.50%
Shares Outstanding: 75.61M
TypeInstitutionsShares
Increased
165
4.33M
New
84
2.06M
Decreased
107
7.04M
Sold Out
46
1.09M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.74%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Chairman/Independent Director
James Young
President/Chief Executive Officer/Director
Stanley Erck
Chief Financial Officer/Executive Vice President/Treasurer
James Kelly
Corporate Executive
Gregory Glenn
Chief Operating Officer/Executive Vice President
Rick Crowley
Chief Human Resource Officer/Executive Vice President
Jill Hoyt
Executive Vice President/Chief Compliance Officer
Troy Morgan
Executive Vice President/Secretary
John Herrmann
Executive Vice President
Filip Dubovsky
Executive Vice President
John Trizzino
Senior Vice President/Director of Sales
Frank Czworka
Senior Vice President/Director of Investor Relations
Silvia Taylor
Senior Vice President
Marco Cacciuttolo
Senior Vice President
Madelyn Caltabiano
Senior Vice President
Nasir Egal
Senior Vice President
Denny Kim
Senior Vice President
Raburn Mallory
Senior Vice President
Brian Rosen
Senior Vice President
Gale Smith
Senior Vice President
Henrietta Ukwu
Senior Vice President
Brian Webb
Director
Rajiv Modi
Independent Director
Gregg Alton
Independent Director
Richard Douglas
Independent Director
Gary Evans
Independent Director
Rachel King
Independent Director
Margaret Mcglynn
Independent Director
Michael Mcmanus
Independent Director
David Mott
No Data
About NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Webull offers kinds of Novavax, Inc. stock information, including NASDAQ:NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.